TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Moleculin Biotech ( (MBRX) ) has shared an update.
On November 20, 2025, Moleculin Biotech received a delist determination letter from Nasdaq, indicating the company had not regained compliance with the minimum stockholders’ equity requirement of $2.5 million. The company plans to appeal this determination to a Nasdaq hearing panel to prevent its securities from being delisted on December 2, 2025, and its common stock will continue to trade under the symbol ‘MBRX’ pending the appeal outcome.
The most recent analyst rating on (MBRX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
Spark’s Take on MBRX Stock
According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.
Moleculin Biotech’s stock score reflects a high-risk financial position with no revenue and growing losses typical of early-stage biotech firms. Positive developments in clinical trials and a solid financial runway provide potential upside, but significant risks remain due to financial instability, high trial costs, and future funding needs. Technical indicators suggest bearish momentum, and the valuation is unattractive due to the absence of earnings.
To see Spark’s full report on MBRX stock, click here.
More about Moleculin Biotech
Moleculin Biotech, Inc. operates in the biotechnology industry, focusing on the development of oncology drug candidates. The company is primarily engaged in creating treatments for highly resistant tumors and other unmet medical needs in the cancer treatment market.
Average Trading Volume: 4,043,789
Technical Sentiment Signal: Sell
Current Market Cap: $22.31M
For detailed information about MBRX stock, go to TipRanks’ Stock Analysis page.